title: miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis.
abstract: Mesenchymal Stromal/Stem Cells (MSC) are currently being explored in diverse clinical applications, including regenerative therapies. Their contribution to regeneration of bone fractures is dependent on their capacity to proliferate, undergo osteogenesis and induce angiogenesis. This study aimed to uncover microRNAs capable of concomitantly regulate these mechanisms. Following microRNA array results, we identified miR-195 and miR-497 as downregulated in human primary MSC under osteogenic differentiation. Overexpression of miR-195 or miR-497 in human primary MSC leads to a decrease in osteogenic differentiation and proliferation rate. Conversely, inhibition of miR-195 increased alkaline phosphatase expression and activity and cells proliferation. Then, miR-195 was used to study MSC capacity to recruit blood vessels in vivo. We provide evidence that the paracrine effect of MSC on angiogenesis is diminishedwhen cells over-express miR-195. VEGF may partially mediate this effect, as its expression and secreted protein levels are reduced by miR-195, while increased by anti-miR-195, in human MSC. Luciferase reporter assays revealed a direct interaction between miR-195 and VEGF 3´-UTR in bone cancer cells. In conclusion, our results suggest that miR-195 regulates important mechanisms for bone regeneration, specifically MSC osteogenic differentiation, proliferation and control of angiogenesis; therefore, it is a potential target for clinical bone regenerative therapies.
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Instituto de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.
authors.forename: Maria Ines
authors.initials: MI
authors.lastname: Almeida
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Instituto de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.|Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
authors.forename: Andreia Machado
authors.initials: AM
authors.lastname: Silva
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Instituto de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.|Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
authors.forename: Daniel Marques
authors.initials: DM
authors.lastname: Vasconcelos
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Instituto de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.
authors.forename: Catarina Rodrigues
authors.initials: CR
authors.lastname: Almeida
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Instituto de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.
authors.forename: Hugo
authors.initials: H
authors.lastname: Caires
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Institute of Molecular Pathology and Immunology of University of Porto (Ipatimup), Porto, Portugal.
authors.forename: Marta Teixeira
authors.initials: MT
authors.lastname: Pinto
authors.affiliation: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: George Adrian
authors.initials: GA
authors.lastname: Calin
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Instituto de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.|Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
authors.forename: Susana Gomes
authors.initials: SG
authors.lastname: Santos
authors.affiliation: Instituto de Investigação e Inovação em Saúde/Institute for Research and Innovation in Health (I3S), University of Porto, Porto, Portugal.|Instituto de Engenharia Biomédica (INEB), University of Porto, Porto, Portugal.|Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
authors.forename: Mário Adolfo
authors.initials: MA
authors.lastname: Barbosa
mesh_terms: D000818:Animals; D001483:Base Sequence; D002454:Cell Differentiation / Q000235:genetics; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics*; D002478:Cells, Cultured; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D020869:Gene Expression Profiling / Q000379:methods; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000378:metabolism*; D051379:Mice; D035683:MicroRNAs / Q000235:genetics*; D018919:Neovascularization, Physiologic / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D010012:Osteogenesis / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012689:Sequence Homology, Nucleic Acid; D013045:Species Specificity; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology
chemical_list: C552722:MIRN195 microRNA, human; C569389:MIRN195a microRNA, mouse; C559640:MIRN497 microRNA, human; D035683:MicroRNAs; D042461:Vascular Endothelial Growth Factor A; C550139:mirn497 microRNA, mouse
keywords: Gerotarget; VEGF; angiogenesis; differentiation; mesenchymal stromal/stem cells; microRNAs